Loading the session
Loading the session
Loading instrument
$50.90
+0.14%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +11.3% (SPY −1.6%). 3 months: +21.2% (SPY −0.4%). 1 year: +15.1% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: QGEN, SPY · as of 4 Nov 2026
The 4 Nov 2026 close of $50.83 was 11.6% above its 50-day average ($45.55) and 19.3% above its 200-day average ($42.60). It has closed above the 200-day for 24 sessions, since 2 Oct 2026. The 50-day average crossed above the 200-day on 21 Sep 2026, 32 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 74.6 on 4 Nov 2026, its 12th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Closed at $50.83 on 4 Nov 2026: 12.1% below the 52-week high of $57.82 (20 Jan 2026) and 56.3% above the low of $32.53 (13 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
7.2M shares were sold short at the 15 Oct 2026 settlement, 3.5% of the 206.1M shares outstanding; covering them would take 3.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
July 9, 2026
+10.50%April 28, 2026
−10.69%January 20, 2026
+16.57%